The South Korea Non-Hodgkin’s Lymphoma market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 6.2% during the forecast period.
Non-Hodgkin’s lymphoma is a type of cancer that begins in lymphatic system, which is part of the body’s immune system. In non-Hodgkin’s lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumours) throughout the body. Non-Hodgkin’s lymphoma is a general category of lymphoma. There are many subtypes that fall in this category. Diffuse large B-cell lymphoma and follicular lymphoma are among the most common subtypes.
According to GLOBOCAN report South Korea reported 5,431 new cases of Non-Hodgkin’s Lymphoma in 2020 and ranked eleventh among other cancer sites. It had the 8th highest death rate with 2,320 death in year 2020 (death rate 2.6%). The five-year prevalence rate was 25.77 per 100,000.
Rise in the prevalence of Non-Hodgkin’s Lymphoma, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for Non-Hodgkin’s Lymphoma therapy drugs are the factors, that are propelling the market growth. Furthermore, an increase in public awareness about Non-Hodgkin’s Lymphoma, strong drug pipeline for the treatment of the disease, improved diagnostic techniques are the factors fuelling the market growth.
However, the high cost of drugs and various complications associated with them are acting as major restraints for the Non-Hodgkin lymphoma market.